U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. INTERCEPT Blood System for Platelets
  1. Approved Blood Products

INTERCEPT Blood System for Platelets

PMA: BP140143
Device Generic Name: Pathogen Reduction System for Platelets
Tradename: INTERCEPT® Blood System for Platelets
Manufacturer: Cerus Corporation
Indications:

  • Intended to be used for ex vivo preparation of apheresis platelet components in order to reduce the risk of transfusion-transmitted infection (TTI) including sepsis, and to potentially reduce the risk of transfusion-associated graft versus host disease (TA-GVHD).

Approval Date: December 18, 2014

Product Information

Supporting Documents

Back to Top